ZNF329

Across TCGA pan-cancer cohorts, ZNF329 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF329 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF329 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF329 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, ESCA, and STAD are the cancer types where ZNF329 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.108	0.687	<.001	20	view →
STAD	OS	Median	II,III,IV	0.416	0.678	.014	12	view →
UCEC	DFS	Median	All	0.933	0.623	.025	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF329–SCLC (OS)

Open the SCLC breakdown →